Clinical acceptability of trimetazidine 80 mg once daily compared to trimetazidine 35 mg twice daily in patients with chronic stable angina pectoris
Not Applicable
Completed
- Conditions
- Angina pectoris attacksCirculatory SystemAngina pectoris
- Registration Number
- ISRCTN84362208
- Lead Sponsor
- Institut de Recherches Internationales Servier (France)
- Brief Summary
2016 poster presentation on http://congress365.escardio.org/Search-Results?vgnextkeyword=C365PRESENTATION140761#.WXi-uriLS70 2018 results in: http://www.ncbi.nlm.nih.gov/pubmed/29779201
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
1. Male or female patient
2. More than or equal to 21 years old
3. Any ethnic origin
4. Patients with a prior diagnosis of stable angina pectoris of effort
Exclusion Criteria
1. History of acute coronary syndrome within previous 3 months
2. Coronary revascularisation procedure within previous 3 months
3. Canadian Cardiovascular Society (CCS) class 4 angina pectoris
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Emergent adverse events <br>2. Blood pressure <br>3. Weight <br>4. Laboratory examinations: biochemical and haematological parameters <br>5.12-lead electrocardiogram <br>6. CCS classification of symptoms of angina pectoris
- Secondary Outcome Measures
Name Time Method o secondary outcome measures